Phencyclidine-induced inhibition of rat prolactin secretion: Increased portal blood dopamine

Herbert Y. Meltzer*, Miljana Simonovic, Gary A. Gudelsky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Intraperitoneal administration of phencyclidine (PCP, 2.5-20 mg/kg) produced a dose-related inhibition of the increase in serum PRL concentrations produced by α-methylparatyrosine (AMPT) or reserpine, but not morphine. Phencyclidine was more potent in antagonizing the PRL-releasing effect of reserpine than that of AMPT, suggesting a greater effect of PCP on the cytoplasmic than the storage dopamine (DA) pool. Phencyclidine had no effect on PRL release from rat pituitary glands in vitro. Intravenous administration of PCP (10 mg/kg) to anesthetized male rats produced a two-fold increase in pituitary stalk (DA) concentrations, suggesting that PCP inhibits rat serum PRL by increasing the release of DA from the tuberoinfundibular neurons, and possibly by blocking its reuptake as well.

Original languageEnglish (US)
Pages (from-to)143-146
Number of pages4
JournalEuropean Journal of Pharmacology
Issue number1
StatePublished - Mar 26 1985


  • Dopamine
  • Phencyclidine
  • Prolactin

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Phencyclidine-induced inhibition of rat prolactin secretion: Increased portal blood dopamine'. Together they form a unique fingerprint.

Cite this